Wright State University
Trial Pipeline
Intranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage
NCT07116408
The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population
NCT06428721
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
NCT06312813
The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy
NCT05688904
DNA Repair Activity in the Skin of Day and Night Shift Workers
NCT04122456
Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects
NCT04520217
Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
NCT04036188
Gene Expression Changes In Young and Geriatric Skin
NCT03932162
Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia
NCT03906253
Sphenopalatine Ganglion Block and Cold Induced Headaches
NCT06310200
Defining N-Acetyl Cysteine as a Treatment for Inhibiting Prurogenic Stimuli
NCT05287724
Pilot Studies Testing Levels of P63 in Psoriasis Skin Lesions
NCT04560647
Post-partum Non-pharmacologic Pain Management
NCT03903172
Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction
NCT02865187
Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation
NCT00906204
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 2 |
| Phase 4 | 1 |
Therapeutic Areas
What the Pipeline for Wright State University Shows
According to the ClinicalTrials.gov registry, Wright State University is linked to 15 US clinical trials across every stage of research activity. Of those, 9 studies are currently recruiting — about 60% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 33% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Wright State University reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 8 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Wright State University is Aging with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.